Rheal A Towner1, Amy B Wisniewski2, Dee H Wu3, Samuel B Van Gordon2, Nataliya Smith4, Justin C North3, Rayburt McElhaney5, Christopher E Aston6, S Abbas Shobeiri7, Bradley P Kropp2, Beverley Greenwood-Van Meerveld8, Robert E Hurst9. 1. Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma; Stephenson Cancer Center, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma. Electronic address: Rheal-Towner@omrf.org. 2. Department of Urology, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma. 3. Department of Radiological Sciences, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma. 4. Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma. 5. Stephenson Cancer Center, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma. 6. Department of Pediatrics, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma. 7. Department of Obstetrics and Gynecology, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma. 8. Department of Physiology, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma. 9. Department of Urology, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma; Department of Biochemistry and Molecular Biology, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma; Stephenson Cancer Center, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma.
Abstract
PURPOSE: Interstitial cystitis/bladder pain syndrome is a bladder pain disorder associated with voiding symptomatology and other systemic chronic pain disorders. Currently diagnosing interstitial cystitis/bladder pain syndrome is complicated as patients present with a wide range of symptoms, physical examination findings and clinical test responses. One hypothesis is that interstitial cystitis symptoms arise from increased bladder permeability to urine solutes. This study establishes the feasibility of using contrast enhanced magnetic resonance imaging to quantify bladder permeability in patients with interstitial cystitis. MATERIALS AND METHODS: Permeability alterations in bladder urothelium were assessed by intravesical administration of the magnetic resonance imaging contrast agent Gd-DTPA (Gd-diethylenetriaminepentaacetic acid) in a small cohort of patients. Magnetic resonance imaging signal intensity in patient and control bladders was compared regionally and for entire bladders. RESULTS: Quantitative assessment of magnetic resonance imaging signal intensity indicated a significant increase in signal intensity in anterior bladder regions compared to posterior regions in patients with interstitial cystitis (p <0.01) and significant increases in signal intensity in anterior bladder regions (p <0.001). Kurtosis (shape of probability distribution) and skewness (measure of probability distribution asymmetry) were associated with contrast enhancement in total bladders in patients with interstitial cystitis vs controls (p <0.05). Regarding symptomatology interstitial cystitis cases differed significantly from controls on the SF-36®, PUF (Pelvic Pain and Urgency/Frequency) and ICPI (Interstitial Cystitis Problem Index) questionnaires with no overlap in the score range in each group. ICSI (Interstitial Cystitis Symptom Index) differed significantly but with a slight overlap in the range of scores. CONCLUSIONS: Data suggest that contrast enhanced magnetic resonance imaging provides an objective, quantifiable measurement of bladder permeability that could be used to stratify bladder pain patients and monitor therapy.
PURPOSE:Interstitial cystitis/bladder pain syndrome is a bladder pain disorder associated with voiding symptomatology and other systemic chronic pain disorders. Currently diagnosing interstitial cystitis/bladder pain syndrome is complicated as patients present with a wide range of symptoms, physical examination findings and clinical test responses. One hypothesis is that interstitial cystitis symptoms arise from increased bladder permeability to urine solutes. This study establishes the feasibility of using contrast enhanced magnetic resonance imaging to quantify bladder permeability in patients with interstitial cystitis. MATERIALS AND METHODS: Permeability alterations in bladder urothelium were assessed by intravesical administration of the magnetic resonance imaging contrast agent Gd-DTPA (Gd-diethylenetriaminepentaacetic acid) in a small cohort of patients. Magnetic resonance imaging signal intensity in patient and control bladders was compared regionally and for entire bladders. RESULTS: Quantitative assessment of magnetic resonance imaging signal intensity indicated a significant increase in signal intensity in anterior bladder regions compared to posterior regions in patients with interstitial cystitis (p <0.01) and significant increases in signal intensity in anterior bladder regions (p <0.001). Kurtosis (shape of probability distribution) and skewness (measure of probability distribution asymmetry) were associated with contrast enhancement in total bladders in patients with interstitial cystitis vs controls (p <0.05). Regarding symptomatology interstitial cystitis cases differed significantly from controls on the SF-36®, PUF (Pelvic Pain and Urgency/Frequency) and ICPI (Interstitial Cystitis Problem Index) questionnaires with no overlap in the score range in each group. ICSI (Interstitial Cystitis Symptom Index) differed significantly but with a slight overlap in the range of scores. CONCLUSIONS: Data suggest that contrast enhanced magnetic resonance imaging provides an objective, quantifiable measurement of bladder permeability that could be used to stratify bladder painpatients and monitor therapy.
Authors: Marc Colaco; David S Koslov; Tristan Keys; Robert J Evans; Gopal H Badlani; Karl-Erik Andersson; Stephen J Walker Journal: J Urol Date: 2014-05-17 Impact factor: 7.450
Authors: Thomas Gevaert; Els Vanstreels; Dirk Daelemans; Jan Franken; Frank Van Der Aa; Tania Roskams; Dirk De Ridder Journal: J Urol Date: 2014-06-02 Impact factor: 7.450
Authors: C Lowell Parsons; Jeffrey Dell; Edward J Stanford; Michael Bullen; Bruce S Kahn; Tracy Waxell; James A Koziol Journal: Urology Date: 2002-10 Impact factor: 2.649
Authors: Rheal A Towner; Nataliya Smith; Debra Saunders; Samuel B Van Gordon; Amy B Wisniewski; Karl R Tyler; Beverley Greenwood-Van Meerveld; Robert E Hurst Journal: J Urol Date: 2014-11-14 Impact factor: 7.450
Authors: Gennady Slobodov; Michael Feloney; Christopher Gran; Kimberly D Kyker; Robert E Hurst; Daniel J Culkin Journal: J Urol Date: 2004-04 Impact factor: 7.450
Authors: Robert E Hurst; Samuel Van Gordon; Karl Tyler; Bradley Kropp; Rheal Towner; HsuehKung Lin; John O Marentette; Jane McHowat; Ehsan Mohammedi; Beverley Greenwood-Van Meerveld Journal: Am J Physiol Renal Physiol Date: 2016-02-24
Authors: Pradeep Tyagi; Joseph J Janicki; T Kevin Hitchens; Lesley M Foley; Mahendra Kashyap; Naoki Yoshimura; Jonathan Kaufman Journal: Am J Physiol Renal Physiol Date: 2017-03-29
Authors: Pradeep Tyagi; Joseph Janicki; Chan-Hong Moon; Jonathan Kaufman; Christopher Chermansky Journal: Int Urol Nephrol Date: 2018-02-01 Impact factor: 2.370
Authors: Rheal A Towner; Nataliya Smith; Debra Saunders; Megan Lerner; Beverley Greenwood-Van Meerveld; Robert E Hurst Journal: Am J Nucl Med Mol Imaging Date: 2020-02-25
Authors: Robert E Hurst; Beverley Greenwood-Van Meerveld; Amy B Wisniewski; Samuel VanGordon; HsuehKung Lin; Bradley P Kropp; Rheal A Towner Journal: Transl Androl Urol Date: 2015-10
Authors: Pradeep Tyagi; Chan-Hong Moon; Joseph Janicki; Jonathan Kaufman; Michael Chancellor; Naoki Yoshimura; Christopher Chermansky Journal: F1000Res Date: 2018-11-09
Authors: Rheal A Towner; Beverley Greenwood-Van Meerveld; Ehsan Mohammadi; Debra Saunders; Nataliya Smith; Grannum R Sant; Harrison C Shain; Thomas H Jozefiak; Robert E Hurst Journal: Pharmacol Res Perspect Date: 2021-02